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The evidence-based guidelines on the management of convulsive status epilepticus in children and adults is a monumental work and a significant contribution to patient care (1) . It presents a careful and thoughtful synthesis of 42 treatment trials encompassing varied comparative effectiveness research strategies, including 4 Cochrane meta-analyses. Therefore, as with any guideline, the developers needed to apply methodology rules as well as medical judgment in their process.
Two important caveats should be noted when applying these guidelines. First, they restricted the guideline to convulsive status epilepticus and did not include nonconvulsive or refractory status epilepticus. The scope of these guidelines should be kept in mind when they are extrapolated to the treatment of related seizure conditions. Second, the authors did not use the American Academy of Neurology (AAN) criteria for determining the strength of the conclusions used to derive the recommendations. The decision was made to accept fewer than the usual number of class I or II studies than the AAN methodology employs to drive high-level recommendations (2) . The stated reason for choosing this method is that it is challenging to conduct randomized, controlled, double-blind status epilepticus studies. This inherently contributes to bias for the available studies providing the truth. However, the lack of evidence does not give more strength to the available evidence. A better and more justifiable reason for this significant deviation from the usual AAN methodology would be that convulsive status epilepticus is clearly observable and even EEG correlation is not needed to make this diagnosis. EEG is not mentioned in this guideline as part of the management approach until the "second therapy" fails, 40 minutes after onset of treatment. Therefore, the effectiveness of treatments as defined by the authors is fairly objective. The outcome of the treatment is clearly observed, so for this reason one might justify an alteration of the usual methodology.
The guideline overall supports an aggressive approach to treating status epilepticus. One important recommendation reflecting this stance is that the initial therapy of benzodiazepines should be administered as an adequate single dose rather than broken into multiple smaller doses. Of importance, hand-in-hand with this recommendation, the evidence shows that for adults, the rate of respiratory depression is lower when patients with status epilepticus are treated with benzodiazepines than with placebo, pointing out the systemic malignancy of convulsive status epilepticus itself. The guideline also states that while phenobarbital is effective as a first treatment, owing to the slow time course of its administration, it is relegated to a position of an "alternative initial therapy rather than a drug of first choice. " Intramuscular (IM) midazolam is incorporated as one of the recommended first choices of treatment. This may be a revolutionary recommendation in that it moves this most expedient intervention to the therapeutic "front burner. " Adoption of this recommendation could truly change the landscape of the outcome of status epilepticus. Bypassing the struggle for intravenous (IV) access in a convulsing patient during a frantic ambulance ride has real-world implications for shutting down the consequences of status epilepticus. Similar implications apply for the recommendations to use rectal diazepam, intranasal midazolam, and buccal midazolam or IM midazolam in the prehospital setting.
The authors present the recommended treatments divided into three sequential 20-minute periods. After the first 5 minutes of initial first aid, the recommended benzodiazepine treatments should be initiated. This is followed by 20 minutes of determining whether the convulsive seizures stop. If the visible seizures do not stop, the second phase of 20 to 40 minutes is addressed, and the "second therapy" starting at 20 minutes is discussed. These include phenytoin, valproate, or levetiracetam, with only valproate achieving a level B recommendation. At the 40-minute mark, the "third-therapy" phase must be considered if convulsive seizures persist. At this point, repeating the second therapy or administering a sedative such as thiopental, midazolam, pentobarbital, or propofol is suggested, although the guideline states there is no evidence to support which medication is best at this point. Continuous EEG at the 40-minute mark is also recommended.
While these 20-minute periods are structurally and intellectually useful, and further, they are derived from the studies used to develop the evidence, are they somewhat contrived? Their translation again to real-world intervention probably breaks down, especially within the first 20-minute period. For example, in many instances of status epilepticus, the second therapy would likely be implemented shortly after the first benzodiazepine treatment within the first 20 minutes, in order to establish a more sustained approach against recurrent seizures. While the first 20 minutes after the benzodiazepine treatment provides a brief window to consider what to do next based on etiology, previous or concurrent medications, and medical status, there is an overriding urgency to stop seizures before the 30-minute mark. This is the well-accepted time point at which seizure-associated neurologic injury ensues.
The need to impose structure on a chaotic and dire medical situation is further evidenced by the new reports from the Task Force of the Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) (3) . The proposed new definition of status epilepticus from this body is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t 1 ). It is a condition, which can have longterm consequences (after time point t 2 ), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. The Task Force further states that for convulsive status epilepticus, t 1 is at 5 minutes and t 2 is at 30 minutes, acknowledging that the evidence for the neurologic consequences at 30 minutes is incomplete. A new diagnostic classification system for status epilepticus is also proposed, comprised of four axes, using a Diagnostic and Statistical Manual (DSBM)structure, including (1) semiology;
(2) etiology; (3) EEG correlates; and (4) age. Therefore, the new report from the American Epilepsy Society, while based on current evidence, does not therapeutically reconcile with the ILAE definition in terms of timing of treatment. Given the current understanding of neurologic risk, these new guidelines clearly inform the real-world application of what sequential treatments to use for status epilepticus; however, when they are used may be along a faster timeline than proposed.
